Regulatory considerations, challenges and risk-based approach in nanomedicine development

I Csóka, R Ismail, O Jójárt-Laczkovich… - Current Medicinal …, 2021 - benthamdirect.com
The translation of nanomedicines from the lab level into marketed product faces several
challenges, including characterization of physicochemical properties, pharmacodynamics …
被引用次数：15 相关文章

Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.

I Csóka, R Ismail, O Jójárt-Laczkovich… - Current Medicinal …, 2021 - europepmc.org
The translation of nanomedicines from the lab level into marketed product faces several
challenges, including characterization of physicochemical properties, pharmacodynamics …

Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development

I Csóka, R Ismail… - Current medicinal …, 2021 - pubmed.ncbi.nlm.nih.gov
The translation of nanomedicines from the lab level into marketed product faces several
challenges, including characterization of physicochemical properties, pharmacodynamics …